- Home
- NTGR vs PHVS Comparison
NTGR vs PHVS Comparison
Compare NTGR & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTGR
- PHVS
- Stock Information
- Founded
- NTGR 1996
- PHVS 2015
- Country
- NTGR United States
- PHVS Netherlands
- Employees
- NTGR N/A
- PHVS N/A
- Industry
- NTGR Telecommunications Equipment
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- NTGR Utilities
- PHVS Health Care
- Exchange
- NTGR Nasdaq
- PHVS Nasdaq
- Market Cap
- NTGR 778.6M
- PHVS 894.8M
- IPO Year
- NTGR N/A
- PHVS 2021
- Fundamental
- Price
- NTGR $26.20
- PHVS $16.49
- Analyst Decision
- NTGR Buy
- PHVS Strong Buy
- Analyst Count
- NTGR 2
- PHVS 5
- Target Price
- NTGR $21.00
- PHVS $41.60
- AVG Volume (30 Days)
- NTGR 476.7K
- PHVS 35.8K
- Earning Date
- NTGR 02-05-2025
- PHVS 04-09-2025
- Dividend Yield
- NTGR N/A
- PHVS N/A
- EPS Growth
- NTGR N/A
- PHVS N/A
- EPS
- NTGR 0.42
- PHVS N/A
- Revenue
- NTGR $673,759,000.00
- PHVS N/A
- Revenue This Year
- NTGR $3.06
- PHVS N/A
- Revenue Next Year
- NTGR $4.86
- PHVS N/A
- P/E Ratio
- NTGR $62.38
- PHVS N/A
- Revenue Growth
- NTGR N/A
- PHVS N/A
- 52 Week Low
- NTGR $10.48
- PHVS $15.21
- 52 Week High
- NTGR $31.55
- PHVS $28.17
- Technical
- Relative Strength Index (RSI)
- NTGR 40.49
- PHVS 36.48
- Support Level
- NTGR $26.14
- PHVS $17.01
- Resistance Level
- NTGR $31.00
- PHVS $17.94
- Average True Range (ATR)
- NTGR 1.48
- PHVS 0.71
- MACD
- NTGR -0.35
- PHVS -0.09
- Stochastic Oscillator
- NTGR 15.49
- PHVS 17.44
About NTGR NETGEAR Inc.
Netgear Inc is a provider of networking solutions. The reportable segments of the company are connected home, and Small and Medium Businesses (SMB). The Connected Home segment focuses on consumers and consists of high-performance, dependable, and easy-to-use 4G/5G mobile, Wi-Fi internet networking solutions, and smart devices such as Orbi Voice smart speakers and Meural digital canvas; and NETGEAR specializes in providing networking solutions for businesses, including wireless LAN, Pro AV applications for audio and video over Ethernet, security, and remote management.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.